Resverlogix Corp. President & CEO Invited to Speak on CNBC's Morning Call.CALGARY, Alberta -- Donald McCaffrey, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Resverlogix Corp. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :RVX), will appear as a guest speaker on CNBC's Morning Call. Morning Call is a leading global business news program airing Monday through Friday from 10:00 a.m. to 12:00 p.m. EST on CNBC CNBC Center for the Neural Basis of Cognition (artificial intelligence) CNBC Consumer News and Business Channel CNBC Congress of National Black Churches, Inc. . Mr. McCaffrey will be addressing the company's lead technology program NEXVAS(TM), and its potential promise in the largest pharmaceutical market segment Cardiovascular Disease. The interview will take place this morning at 11:45 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy on Tuesday February 22nd. "It is a privilege for Resverlogix to be on CNBC and share our insights on the exciting new area of HDL (Hardware Description Language) A language used to describe the functions of an electronic circuit for documentation, simulation or logic synthesis (or all three). Although many proprietary HDLs have been developed, Verilog and VHDL are the major standards. enhancing compounds and the potential they hold for future cardiovascular medicine," stated Donald McCaffrey. "This is a very exciting time for the biotechnology and life sciences industry especially as HDL enhancement technologies have shown the ability to actually reduce atherosclerotic plaque, one of the major causes of coronary heart disease coronary heart disease: see coronary artery disease. coronary heart disease or ischemic heart disease Progressive reduction of blood supply to the heart muscle due to narrowing or blocking of a coronary artery (see atherosclerosis). ." About Resverlogix Corp. Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology program NEXVAS(TM) applies advanced medical research to develop therapies that increase high density lipoprotein High density lipoprotein (HDL) A fraction of total serum lipids, the so called "good" cholesterol. Mentioned in: Hypercholesterolemia (HDL), the "good cholesterol," to treat cardiovascular diseases. The corporation's second technology program TGF-Beta Shield(TM) utilizes an adoptive immunotherapy approach to target cancers and fibrotic diseases. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet medical need. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com. This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not except responsibility for the adequacy or accuracy of this news release. Resverlogix Corp. (TSX:RVX) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion